Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedApr 21, 2026
DataAggregated Company Financials
Companies7
  • 7D1.6%
  • 3M-2.6%
  • 1Y1.3%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 4.6%, with Lonza Group up 1.7%. This takes the industry's 12 month performance to a gain of 4.3%. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 21 Apr 2026CHF 49.6bCHF 10.1bCHF 1.1b34.9x43.4x4.9x
Thu, 19 Mar 2026CHF 45.3bCHF 10.1bCHF 1.1b31.4x39.6x4.5x
Sat, 14 Feb 2026CHF 49.2bCHF 10.1bCHF 1.3b31.2x38.6x4.9x
Mon, 12 Jan 2026CHF 51.4bCHF 10.6bCHF 1.1b32.7x46.7x4.8x
Wed, 10 Dec 2025CHF 49.0bCHF 10.7bCHF 1.1b28.3x44.6x4.6x
Fri, 07 Nov 2025CHF 48.1bCHF 10.6bCHF 1.1b27.9x43.8x4.5x
Sun, 05 Oct 2025CHF 51.1bCHF 10.6bCHF 1.1b31.7x46.5x4.8x
Tue, 02 Sep 2025CHF 53.2bCHF 10.7bCHF 1.1b34.1x48.3x5x
Thu, 31 Jul 2025CHF 54.6bCHF 10.7bCHF 1.1b35x47.5x5.1x
Sat, 28 Jun 2025CHF 52.8bCHF 10.1bCHF 1.0b33.6x50.8x5.2x
Mon, 26 May 2025CHF 51.8bCHF 10.1bCHF 1.0b30.8x49.9x5.1x
Wed, 23 Apr 2025CHF 50.1bCHF 10.1bCHF 1.0b28.2x48.9x5x
Fri, 21 Mar 2025CHF 53.5bCHF 10.1bCHF 1.0b33.5x52.6x5.3x
Sun, 16 Feb 2025CHF 57.1bCHF 10.1bCHF 1.0b36.4x56.7x5.7x
Tue, 14 Jan 2025CHF 53.3bCHF 10.2bCHF 943.4m34.7x56.5x5.2x
Thu, 12 Dec 2024CHF 52.6bCHF 10.2bCHF 943.7m39.1x55.7x5.2x
Sat, 09 Nov 2024CHF 55.9bCHF 10.2bCHF 943.4m43.8x59.2x5.5x
Mon, 07 Oct 2024CHF 54.4bCHF 10.2bCHF 943.3m41.8x57.6x5.3x
Wed, 04 Sep 2024CHF 56.6bCHF 10.2bCHF 937.1m44.6x60.4x5.5x
Fri, 02 Aug 2024CHF 59.9bCHF 10.2bCHF 923.9m45.6x64.8x5.8x
Sun, 30 Jun 2024CHF 51.2bCHF 10.3bCHF 1.0b44x51.1x5x
Tue, 28 May 2024CHF 54.5bCHF 10.3bCHF 1.0b45.1x54.5x5.3x
Thu, 25 Apr 2024CHF 54.9bCHF 10.3bCHF 1.0b43.8x54.8x5.3x
Sat, 23 Mar 2024CHF 57.2bCHF 10.2bCHF 1.0b45.9x56.9x5.6x
Mon, 19 Feb 2024CHF 49.9bCHF 10.2bCHF 1.0b45.9x49x4.9x
Wed, 17 Jan 2024CHF 42.2bCHF 9.8bCHF 1.5b31.4x28.3x4.3x
Fri, 15 Dec 2023CHF 40.3bCHF 9.8bCHF 1.5b32x27x4.1x
Sun, 12 Nov 2023CHF 39.6bCHF 9.8bCHF 1.5b27.5x26.5x4x
Tue, 10 Oct 2023CHF 46.7bCHF 9.8bCHF 1.5b31.6x31.2x4.8x
Thu, 07 Sep 2023CHF 53.2bCHF 9.8bCHF 1.5b36.6x35.6x5.4x
Sat, 05 Aug 2023CHF 52.9bCHF 9.8bCHF 1.5b35.3x34.2x5.4x
Mon, 03 Jul 2023CHF 55.6bCHF 9.7bCHF 1.6b36.2x34x5.7x
Wed, 31 May 2023CHF 59.6bCHF 9.7bCHF 1.6b37.7x36.4x6.2x
Fri, 28 Apr 2023CHF 58.5bCHF 9.7bCHF 1.6b40.6x35.8x6x
Price to Earnings Ratio

35.8x


Total Market Cap: CHF 58.5bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 46.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.1x.
  • The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 11% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market0.98%
Healthcare0.066%
Life Sciences1.60%
Clinical Research and Equipment1.60%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 526.001.7%
+CHF 628.6m		-2.4%PE40.4x
SKAN SKAN GroupCHF 48.608.8%
+CHF 88.8m		-22.6%PE67.1x
SFZN Siegfried HoldingCHF 81.752.5%
+CHF 87.6m		-8.0%PE21.2x
XLS Xlife SciencesCHF 22.5012.5%
+CHF 14.4m		12.5%PE4.2x
TECN Tecan GroupCHF 135.500.7%
+CHF 12.5m		-4.6%PS1.9x

Latest News

SFZN
CHF 81.75
Siegfried Holding
7D
2.5%
1Y
-8.0%
XLS
CHF 22.50
Xlife Sciences
7D
12.5%
1Y
12.5%
TECN
CHF 135.50
Tecan Group
7D
0.7%
1Y
-4.6%

TECN: AI Lab Collaboration And Execution Discipline Will Support Future Earnings

The analyst price target for Tecan Group has shifted slightly to around CHF 167, with recent CHF 1 and CHF 17 target reductions from different firms. These moves have led analysts to fine tune assumptions on discount rate, revenue growth, profit margin and future P/E, without changing the overall valuation picture in a major way.
BANB
CHF 69.35
Bachem Holding
7D
-0.6%
1Y
46.5%

BANB: Future Upside Will Depend On Executing Profit Margin Assumptions

Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.
LONN
CHF 526.00
Lonza Group
7D
1.7%
1Y
-2.4%
SKAN
CHF 48.60
SKAN Group
7D
8.8%
1Y
-22.6%
PPGN
CHF 35.40
PolyPeptide Group
7D
-1.4%
1Y
112.0%